Cancer Treatment Today

Both allogeneic(from another human) and autologous9from the self) hematopoietic cell transplant (HCT) recipients are at increased risk for a variety of infections based upon their past history and exposures, more so the allogeneic transplant recipients. The types of infections to which these hosts are most vulnerable can be roughly divided based upon their temporal relation to the transplantation: ?Preengraftment — less than three weeks ?Immediate

Medulloblastoma is a brain cancer that  is treated primarily with surgical excision followed by radiation therapy and chemotherapy. When there is spinal extension, craniospinal(brain and spine) radiation is standard. Inoperable medulloblastomas are often treated with chemotherapy but there is no randomized prospective evidence to support this. This is especially so in adults, in whom this disease is less common than in children and in whom it appears

Acute Lymphocytic Leukemia(ALL) is the most common cancer diagnosed in children and represents almost 25% of cancers in children younger than 15 years. Complete remission of disease is now typically achieved with pediatric chemotherapy regimens in approximately 95% of children with ALL, with up to 85% long-term survival rates. Interestingly, recent studies appears to show that young adults with ALL do better with pediatric regimens and specifically

Neupogen(filgrastim)  is often used to drive progenitor cells into the peripheral blood so they can collected by the leukophereses for use in a stem cell transplant. It is FDA approved for this purpose. Regarding dose, please look at the professional version. How long should Neupogen be used? It is recommended that NEUPOGEN® (filgrastim) be given for at least 4 days before the first leukapheresis procedure and continued until the last leukapheresis.